Mercado Europeu da Dor Neuropática – Tendências da Indústria e Previsão para 2030

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado Europeu da Dor Neuropática – Tendências da Indústria e Previsão para 2030

  • Healthcare
  • Upcoming Reports
  • Sep 2023
  • Europe
  • 350 Páginas
  • Número de tabelas: 220
  • Número de figuras: 60

Europe Neuropathic Pain Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Diagram Período de previsão
2023 –2030
Diagram Tamanho do mercado (ano base )
USD 1,123.93 million
Diagram Tamanho do mercado ( Ano de previsão)
USD 2,371.40 million
Diagram CAGR
%
Diagram Principais participantes do mercado
  • Manequim1
  • Manequim2
  • Manequim3
  • Manequim4
  • Manequim5

>Mercado europeu da dor neuropática, por tipo (dispositivos de estimulação da medula espinal (SCS), estimulação nervosa periférica externa, dispositivos de estimulação elétrica nervosa transcutânea (dezenas), tipo de produto (recarregável e não recarregável), procedimento (invasivo e não invasivo ), Tecnologia (estimulação elétrica nervosa transcutânea, estimulação magnética transcraniana e estimulação elétrica respiratória), modalidade (estacionária e portátil), modo de compra (dispositivos de venda livre e dispositivos baseados em prescrição), tipo de dor (neuropatia periférica, neuropatia por aprisionamento , fantasma Neuropatia dos membros, neuralgia do trigémeo, neuralgia pós-herpética (NPH), neuropatia pós-traumática, dor nos pés, coccidínia), indicação (estenose espinal, neuropatia periférica induzida por quimioterapia, neuropatia diabética, outros), utilizador final ( hospitais, clínicas, cuidados de saúde domiciliários, Centros Cirúrgicos de Ambulatório e Outros), Canal de Distribuição (Concurso Directo, Distribuidor Terceirizado e Outros) – Tendências e Previsão do Sector para 2030.

 Mercado Europeu da Dor Neuropática

Análise e dimensão do mercado da dor neuropática na Europa

Espera-se que o aumento dos gastos em I&D por parte de vários participantes do mercado para criar produtos avançados impulsione o crescimento do mercado europeu da dor neuropática. Prevê-se que a limitação associada aos dispositivos médicos que limita a utilização de produtos atue como restrição para o crescimento do mercado europeu da dor neuropática. O elevado risco de dor neuropática com o envelhecimento e o aumento da população idosa em muitos países criará uma oportunidade para o crescimento do mercado europeu da dor neuropática. Espera-se que a utilização de terapêuticas tradicionais nos países emergentes devido aos baixos gastos em saúde e à perturbação da cadeia de abastecimento atue como um desafio para o crescimento do mercado europeu da dor neuropática.

A Data Bridge Market Research analisa que o mercado europeu da dor neuropática, que foi de 1.123,93 milhões de dólares em 2022, deverá atingir os 2.371,40 milhões de dólares até 2030, e deverá passar por um CAGR de 9,1% durante o período de previsão de 2023 a 2030. “ O segmento dos dispositivos de estimulação da medula espinal (SCS) domina o segmento de tipo do mercado europeu da dor neuropática devido aos avanços na tecnologia. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado europeu da dor neuropática

Métrica de relatório

Detalhes

Período de previsão

2023 a 2030

Ano base

2022

Anos históricos

2021 (personalizável para 2015-2020)

Unidades Quantitativas

Receita em milhões de dólares, volumes em unidades, preços em dólares

Segmentos cobertos

Tipo (dispositivos de estimulação da medula espinal (SCS), estimulação de nervos periféricos externos, dispositivos de estimulação elétrica nervosa transcutânea (dezenas)), tipo de produto (recarregável e não recarregável), procedimento (invasivo e não invasivo), tecnologia (estimulação elétrica nervosa transcutânea , estimulação magnética transcraniana e estimulação elétrica respiratória), modalidade (estacionária e portátil), modo de compra (dispositivos de venda livre e dispositivos baseados em prescrição), tipo de dor ( neuropatia periférica , neuropatia de aprisionamento, neuropatia de membro fantasma , nevralgia do trigémeo, Neuralgia Pós-Herpética (NPH), Neuropatia Pós-Traumática, Dor nos Pés, Coccidínia), Indicação (Estenose Espinhal, Neuropatia Periférica Induzida por Quimioterapia, Neuropatia Diabética , Outros), Utilizador Final (Hospitais, Clínicas, Assistência Domiciliário, Centros Cirúrgicos Ambulatório e Outros) , Canal de Distribuição (Concurso Directo, Distribuidor Terceirizado e Outros)

Países abrangidos

Alemanha, França, Reino Unido, Holanda, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa

Participantes do mercado abrangidos

(EUA), Boston Scientific Corporation (EUA), Abbott (EUA), electroCore, Inc. (EUA), Polar Medical (Inglaterra), B. Braun Melsungen AG (Alemanha), Omron Healthcare, Inc., Cirtec (EUA), Medtronic (Irlanda), Pfizer Inc. (EUA), Novartis AG (Suíça), Virpax Pharmaceuticals, Inc. )

Oportunidades de mercado

  • Sensibilização crescente dos pacientes
  • Aumento das despesas com a saúde
  • Aumento das iniciativas estratégicas por parte dos principais players do mercado

Definição de mercado

A dor neuropática é causada por uma lesão ou doença do sistema somatossensorial, incluindo fibras periféricas (fibras Aβ, Aδ e C) e neurónios centrais e afeta 7–10% da população em geral. Têm sido descritas múltiplas causas de dor neuropática e é provável que a sua incidência aumente devido ao envelhecimento da população global, ao aumento da incidência de diabetes mellitus e à melhoria da sobrevivência ao cancro após a quimioterapia.

Dinâmica do mercado da dor neuropática na Europa

Motoristas

  • Aumento da prevalência de dor neuropática

À medida que a população idosa cresce e as doenças crónicas, como a diabetes e o cancro, se tornam mais prevalentes, o número de pessoas que sofrem de dor neuropática aumenta. Esta tendência demográfica impulsiona a procura de tratamentos e medicamentos para a dor neuropática.

  • Avanços na investigação médica

A investigação contínua sobre as causas e mecanismos da dor neuropática levou ao desenvolvimento de novas opções de tratamento e terapias. À medida que a nossa compreensão da dor neuropática melhora, estão a ser desenvolvidos tratamentos mais eficazes, criando oportunidades para as empresas farmacêuticas e de biotecnologia.

  • Desenvolvimento de novos medicamentos

As empresas farmacêuticas estão a investir no desenvolvimento de novos medicamentos especificamente concebidos para combater a dor neuropática. Estes medicamentos têm como objetivo proporcionar um melhor alívio da dor com menos efeitos secundários, melhorando a qualidade de vida dos doentes.

Oportunidades

  • Consciência crescente entre os doentes

O aumento da consciencialização sobre a dor neuropática e o seu impacto na vida dos doentes levou a uma maior procura por tratamentos eficazes. Os doentes estão a tornar-se mais proativos na procura de cuidados e terapias adequadas.

  • Aumento das despesas com a saúde

À medida que as despesas com cuidados de saúde continuam a aumentar a nível mundial, há mais financiamento disponível para investigação, desenvolvimento e acesso a tratamentos e terapias para a dor neuropática.

Restrições/Desafios

  • Eficácia limitada dos tratamentos atuais

Muitos medicamentos e terapias existentes para a dor neuropática oferecem apenas um alívio parcial e podem ter efeitos secundários. Esta eficácia limitada pode levar à insatisfação do doente e à procura de tratamentos alternativos.

  • Efeitos secundários e preocupações de segurança

Alguns medicamentos para a dor neuropática, incluindo os opióides e certos antidepressivos, podem causar efeitos secundários como sonolência, tonturas e dependência. Gerir estes efeitos secundários pode ser um desafio tanto para os doentes como para os profissionais de saúde.

Este relatório do mercado europeu de dor neuropática fornece detalhes dos novos desenvolvimentos recentes, regulamentos comerciais, análise de importação-exportação, análise de produção, otimização da cadeia de valor, quota de mercado, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado, análise estratégica do crescimento do mercado, tamanho do mercado, crescimento do mercado da categoria, nichos de aplicação e domínio, aprovações de produtos, lançamentos de produtos, expansões geográficas, inovações tecnológicas no mercado. Para mais informações sobre o mercado europeu da dor neuropática, contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a tomar uma decisão de mercado informada para alcançar o crescimento do mercado.

Desenvolvimentos recentes

  • Em janeiro de 2023, a Abbott anunciou que a Food and Drug Administration (FDA) dos EUA aprovou o seu sistema Proclaim XR de estimulação da medula espinhal (SCS) para tratar a neuropatia periférica diabética dolorosa (DPN), uma complicação debilitante da diabetes.
  •  Em julho de 2022, a Vertex Pharmaceuticals Incorporated anunciou resultados positivos de Fase 2 do VX-548 na dor aguda e neuropática pela US Food and Drug Administration (FDA)

Âmbito do mercado de dor neuropática da Europa

O mercado europeu da dor neuropática está segmentado com base no tipo, tipo de produto, procedimento, tecnologia, modalidade, modo de compra, tipo de dor, indicação, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar os escassos segmentos de crescimento nas indústrias e fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.

Tipo

  • Dispositivos de estimulação da medula espinal (SCS)
  • Estimulação do nervo periférico externo
  • Dispositivos de estimulação elétrica nervosa transcutânea (dezenas)

Tipo de produto

  • Recarregável
  • Não recarregável

Procedimento

  • Invasivo
  • Não invasivo

Tecnologia

  • Estimulação Elétrica Nervosa Transcutânea
  • Estimulação Magnética Transcraniana
  • Estimulação Elétrica Respiratória

Modalidade

  • Estacionário
  • Portable

Mode of Purchase

  • Over-the-Counter Devices
  • Prescription-Based Devices

Pain Type

  • Peripheral Neuropathy
  • Entrapment Neuropathy
  • Phantom Limb Neuropathy
  • Trigeminal Neuralgia
  • Post Herpetic Neuralgia (PHN)
  • Post Traumatic Neuropathy
  • Foot Pain
  • Coccydynia

Indication

  • Spinal Stenosis
  • Chemotherapy-Induced Peripheral Neuropathy
  • Diabetic Neuropathy
  • Others

End User

Distribution Channel

  • Direct Tender
  • Third Party Distributor
  • Others

Europe Neuropathic Pain Market Regional Analysis/Insights

The Europe neuropathic pain market is analysed and market size insights and trends are provided by country, type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end user, and distribution channel as referenced above.

The countries covered in the Europe neuropathic pain market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and Rest of Europe

Germany dominates the Europe neuropathic pain market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.   

Germany is expected to witness significant growth in the Europe neuropathic pain market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Europe neuropathic pain market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Europe neuropathic pain market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Europe neuropathic pain market. The data is available for historic period 2015-2020.

Competitive Landscape and Europe Neuropathic Pain Market Share Analysis

O panorama competitivo do mercado europeu da dor neuropática fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado europeu da dor neuropática.

Alguns dos principais players que operam no mercado europeu da dor neuropática são:

  • NEVRO CORP.
  •  Corporação Científica de Boston (EUA)
  •  Abbott (EUA)
  •  electroCore, Inc.
  •  Polar Médica (Inglaterra)
  •  B. Braun Melsungen AG (Alemanha)
  •  (Japão)
  •  Cirtec (EUA)
  •  Medtronic (Irlanda)
  • (EUA)
  •  Novartis AG (Suíça)
  •  Virpax Pharmaceuticals, Inc.
  •  Amgen Inc.(EUA)
  • Integer Holdings Corporation (EUA)
  •  AVNS (EUA) 


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of EUROPE Neuropathic pain MARKET
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. type LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. vendor share analysis
    11. MARKET type of manufacturer COVERAGE GRID
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insight
  5. regulation
    1. REGULATORY GUIDELINES AS PER USFDA
    2. REGULATORY GUIDELINES AS PER EUROPEAN UNION
  6. market overview
    1. drivers
      1. Growing prevalence of chronic pain and neuropathic condition
      2. Increasing Cases Of Diabetic Neuropathy
      3. Increasing R&D Expenditure
      4. Advancement In New Neuromodulation Technology
      5. Penetration Of the New Market Players
    2. RESTRAINTS
      1. High cost of the medical devices
      2. Low awareness for neuropathic pain devices
      3. unfavorable government policies
      4. Limitation of Neuropathic medical Devices
    3. OPPORTUNITIES
      1. High Risk Of Neuropathic Pain With Ageing
      2. Government initiatives for neuropathic pain
      3. Appropriate Reimbursement policy for the medical devices
    4. CHALLENGES
      1. Dearth of skilled professionals
      2. Use of traditional therapy in emerging economies
  7. IMPACT OF COVID-19 ON THE EUROPE NEUROPATHIC PAIN MARKET
    1. OVERVIEW
    2. IMPACT ON PRICE
    3. IMPACT ON SUPPLY
    4. STRATEGIC DECISIONS BY MANUFACTURERS
    5. CONCLUSION-
  8. europe Neuropathic pain MARKET, BY Type
    1. overview
    2. SPINAL CORD STIMULATION (SCS) DEVICES
      1. Rechargeable Implantable Pulse Generator
      2. Radiofrequency Stimulator
      3. Conventional Implantable Pulse Generator/ IPG
    3. EXTERNAL PERIPHERAL NERVE STIMULATION
      1. Deep Brain Stimulators (DBS)
        1. Dual-Channel Deep Brain Stimulator
        2. Single-Channel Deep Brain Stimulator
      2. Transcranial Magnetic Stimulators (TMS)
      3. Vagus Nerve Stimulators (VNS)
      4. Sacral Nerve Stimulators (SNS)
    4. TRANSCUTANEOUS ELECTRIC NERVE STIMULATION (TENS) DEVICES
      1. Conventional Tens (Low-intensity, High-Frequency)
      2. Acupuncture-Like Tens (High-Intensity, Low-Frequency)
      3. Intense Tens (High-Intensity, High-Frequency)
  9. europe Neuropathic pain MARKET, BY product type
    1. overview
    2. rechargeable
    3. non- rechargeable
  10. europe Neuropathic pain MARKET, BY Procedure
    1. overview
    2. Non-Invasive
    3. invasive
  11. europe Neuropathic pain MARKET, BY technology
    1. overview
    2. TRANSCUTANEOUS ELECTRIC NERVE STIMULATION
    3. TRANSCRANIAL MAGNETIC STIMULATION
    4. Respiratory Electrical Stimulation
  12. europe Neuropathic pain MARKET, BY Modality
    1. overview
    2. portable
      1. Rechargeable
      2. Non- Rechargeable
    3. stationary
      1. Rechargeable
      2. Non- Rechargeable
  13. europe Neuropathic pain MARKET, BY Mode of Purchase
    1. overview
    2. Prescription-Based Devices
    3. Over-The-Counter Devices
  14. europe Neuropathic pain MARKET, BY Pain Type
    1. overview
    2. Peripheral Neuropathy
    3. Phantom Limb Pain
    4. Post Herpetic Neuralgia (PHN)
    5. Post Traumatic Neuropathy
    6. Entrapment Neuropathy
    7. Foot Pain
    8. Trigeminal Neuralgia
    9. Coccydynia
    10. others
  15. europe Neuropathic pain MARKET, BY indication
    1. overview
    2. Spinal Stenosis
      1. Spinal Cord Stimulation (SCS) Devices
      2. Transcutaneous Electrical Nerve Stimulation (TENS) devices
      3. External Peripheral Nerve Stimulation
    3. Diabetic Neuropathy
      1. Spinal Cord Stimulation (SCS) Devices
      2. Transcutaneous Electrical Nerve Stimulation (TENS) devices
      3. External Peripheral Nerve Stimulation
    4. Chemotherapy-Induced Peripheral Neuropathy
      1. Spinal Cord Stimulation (SCS) Devices
      2. Transcutaneous Electrical Nerve Stimulation (TENS) devices
      3. External Peripheral Nerve Stimulation
    5. others
  16. europe Neuropathic pain MARKET, BY end user
    1. overview
    2. Clinics
    3. Hospitals
      1. Acute Care Hospitals
      2. Long-Term Care Hospitals
      3. Nursing Facilities
      4. Rehabilitation Centers
    4. Home Healthcare
    5. Ambulatory Surgical Centers
    6. others
  17. europe Neuropathic pain MARKET, BY distribution channel
    1. overview
    2. Direct Tenders
    3. Third Party Distribution
    4. others
  18. Europe neuropathic Pain market by geography
    1. Overview
    2. EUROPE
      1. GERMANY
      2. france
      3. U.K.
      4. Italy
      5. Russia
      6. Spain
      7. Netherlands
      8. Turkey
      9. Switzerland
      10. Rest of Europe
  19. Europe Neuropathic Pain Market: COMPANY landscape
    1. company share analysis: europe
  20. swot analysis
  21. Company profile
    1. medtronic
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    2. boston scientific corporation
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    3. ABBOTT
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    4. nervo corp.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    5. omron healthcare, INC.
      1. COMPANY SNAPSHOT
      2. company share analysis
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    6. Interger holdings corporation
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    7. avns
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    8. b.braun melsungen AG
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    9. Cirtec
      1. 257
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    10. ELECTROCORE, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    11. Neurometrix, inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    12. Polar medical
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    13. Spr therapeutics
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    14. Stimwave LLC.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    15. sunmed
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
  22. questionnaire
  23. related reports

Lista de Tabela

TABLE 1 Europe Neuropathic Pain Market, By Type, 2019-2028 (USD Million)

TABLE 2 Europe Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)

TABLE 3 Europe Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)

TABLE 4 Europe External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)

TABLE 5 Europe External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)

TABLE 6 Europe Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)

TABLE 7 Europe Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)

TABLE 8 Europe Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)

TABLE 9 Europe Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)

TABLE 10 Europe Rechargeable in Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)

TABLE 11 Europe Non-Rechargeable Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)

TABLE 12 Europe Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)

TABLE 13 Europe Non-Invasive Invasive in Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)

TABLE 14 Europe Invasive in Neuroendocrine Tumors Market, By Classification 2019-2027 (USD Million)

TABLE 15 Europe Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)

TABLE 16 Europe Transcutaneous Electrical Nerve Stimulation Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)

TABLE 17 Europe Transcranial Magnetic Stimulation Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)

TABLE 18 Europe Respiratory Electrical Stimulation Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)

TABLE 19 Europe Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)

TABLE 20 Europe Portable Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)

TABLE 21 Europe Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)

TABLE 22 Europe Stationary Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)

TABLE 23 Europe Stationary Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)

TABLE 24 Europe Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)

TABLE 25 Europe Prescription-Based Devices Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)

TABLE 26 Europe Over-The-Counter Devices Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)

TABLE 27 Europe Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 28 Europe Peripheral Neuropathy Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 29 Europe Phantom Limb Pain Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 30 Europe Post Herpetic Neuralgia (PHN) Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 31 Europe Post Traumatic NeuropathyNeuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 32 Europe Entrapment Neuropathy Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 33 Europe Foot Pain Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 34 Europe Trigeminal Neuralgia Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 35 Europe Coccydynia Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 36 Europe Others Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)

TABLE 37 Europe Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)

TABLE 38 Europe Spinal Stenosis Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)

TABLE 39 Europe Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)

TABLE 40 Europe Diabetic Neuropathy Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)

TABLE 41 Europe Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)

TABLE 42 Europe Chemotherapy-Induced Peripheral Neuropathy Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)

TABLE 43 Europe Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)

TABLE 44 Europe Others Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)

TABLE 45 Europe Neuropathic Pain Market, By End User, 2019-2028 (USD Million)

TABLE 46 Europe Clinics Neuropathic Pain Market, By End User, 2019-2028 (USD Million)

TABLE 47 Europe Hospitals Neuropathic Pain Market, By End User, 2019-2028 (USD Million)

TABLE 48 Europe Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)

TABLE 49 Europe Home Healthcare Neuropathic Pain Market, By End User, 2019-2028 (USD Million)

TABLE 50 Europe Ambulatory Surgical Centers Neuropathic Pain Market, By End User, 2019-2028 (USD Million)

TABLE 51 Europe Others Neuropathic Pain Market, By End User, 2019-2028 (USD Million)

TABLE 52 Europe Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 53 Europe Direct Tenders Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 54 Europe Third Party Distribution Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 55 Europe Others Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 56 EUROPE neuropathic Pain MARKET, BY REGION , 2021-2028 (USD MILLION)

TABLE 57 Europe NEUROPATHIC PAIN MARKET, By Region, 2019-2028 (USD Million)

TABLE 58 EUROPE NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 59 EUROPE Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 60 EUROPE External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 61 EUROPE Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 62 EUROPE Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 63 EUROPE NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 64 EUROPE NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 65 EUROPE NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 66 EUROPE NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 67 EUROPE Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 68 EUROPE portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 69 EUROPE NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 70 EUROPE NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 71 EUROPE NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 72 EUROPE SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 73 EUROPE Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 74 EUROPE Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 75 EUROPE NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 76 EUROPE hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 77 EUROPE NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 78 GERMANY NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 79 GERMANY Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 80 GERMANY External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 81 germany Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 82 GERMANY Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 83 GERMANY NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 84 GERMANY NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 85 GERMANY NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 86 GERMANY NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 87 GERMANY Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 88 GERMANY portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 89 GERMANY NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 90 GERMANY NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 91 GERMANY NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 92 GERMANY SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 93 GERMANY Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 94 GERMANY Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 95 GERMANY NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 96 GERMANY hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 97 GERMANY NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 98 france NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 99 france Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 100 france External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 101 france Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 102 france Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 103 france NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 104 france NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 105 france NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 106 france NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 107 france Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 108 france portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 109 france NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 110 france NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 111 france NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 112 france SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 113 france Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 114 france Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 115 france NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 116 france hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 117 france NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 118 U.K. NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 119 U.K. Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 120 U.K. External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 121 U.K. Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 122 U.K. Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 123 U.K. NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 124 U.K. NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 125 U.K. NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 126 U.K. NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 127 U.K. Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 128 U.K. portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 129 U.K. NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 130 U.K. NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 131 U.K. NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 132 U.K. SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 133 U.K. Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 134 U.K. Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 135 U.K. NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 136 U.K. hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 137 U.K. NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 138 italy NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 139 italy Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 140 italy External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 141 italy Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 142 italy Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 143 italy NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 144 italy NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 145 italy NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 146 italy NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 147 italy Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 148 italy portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 149 italy NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 150 italy NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 151 italy NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 152 italy SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 153 italy Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 154 italy Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 155 italy NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 156 italy hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 157 italy NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 158 russia NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 159 russia Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 160 russia External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 161 russia Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 162 russia Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 163 russia NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 164 russia NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 165 russia NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 166 russia NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 167 russia Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 168 russia portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 169 russia NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 170 russia NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 171 russia NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 172 russia SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 173 russia Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 174 russia Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 175 russia NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 176 russia hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 177 russia NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 178 spain NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 179 spain Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 180 spain External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 181 spain Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 182 spain Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 183 spain NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 184 spain NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 185 spain NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 186 spain NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 187 spain Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 188 spain portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 189 spain NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 190 spain NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 191 spain NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 192 spain SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 193 spain Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 194 spain Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 195 russia NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 196 spain hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 197 spain NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 198 Netherlands NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 199 Netherlands Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 200 Netherlands External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 201 Netherlands Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 202 Netherlands Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 203 Netherlands NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 204 Netherlands NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 205 Netherlands NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 206 Netherlands NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 207 Netherlands Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 208 Netherlands portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 209 Netherlands NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 210 Netherlands NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 211 Netherlands NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 212 Netherlands SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 213 Netherlands Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 214 Netherlands Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 215 Netherlands NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 216 Netherlands hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 217 Netherlands NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 218 turkey NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 219 turkey Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 220 turkey External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 221 turkey Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 222 turkey Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 223 turkey NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 224 turkey NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 225 turkey NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 226 turkey NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 227 turkey Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 228 turkey portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 229 turkey NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 230 turkey NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 231 turkey NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 232 turkey SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 233 turkey Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 234 turkey Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 235 turkey NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 236 turkey hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 237 turkey NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 238 Switzerland NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 239 Switzerland Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 240 Switzerland External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 241 Switzerland Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 242 Switzerland Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

TABLE 243 Switzerland NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)

TABLE 244 Switzerland NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)

TABLE 245 Switzerland NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)

TABLE 246 Switzerland NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 247 Switzerland Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 248 Switzerland portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)

TABLE 249 Switzerland NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)

TABLE 250 Switzerland NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)

TABLE 251 Switzerland NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 252 Switzerland SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 253 Switzerland Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 254 Switzerland Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)

TABLE 255 Switzerland NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 256 Switzerland hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)

TABLE 257 Switzerland NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)

TABLE 258 Rest of Europe NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)

Lista de Figura

FIGURE 1 Europe NEUROPATHIC PAIN MARKET: SEGMENTATION

FIGURE 2 EUROPE NEUROPATHIC PAIN MARKET: DATA TRIANGULATION

FIGURE 3 europe Neuropathic pain Market: DROC ANALYSIS

FIGURE 4 Europe Neuropathic pain market: Europe VS REGIONAL MARKET ANALYSIS

FIGURE 5 Europe Neuropathic pain Market: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE Neuropathic pain MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE Neuropathic pain MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE NEUROPATHIC PAIN MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE NEUROPATHIC PAIN MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE Neuropathic pain MARKET: MARKET type COVERAGE GRID

FIGURE 11 Europe Neuropathic pain market: SEGMENTATION

FIGURE 12 NORTH AMERICA is expected to DOMINATE THE EUROPE Neuropathic pain market AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 GROWING PREVALENCE OF CHRONIC PAIN, NEUROPATHIC CONDITION, AND INCREASING CASES OF DIABETIC NEUROPATHY IS DRIVING THE EUROPE NEUROPATHIC PAIN MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 SPINAL CORD STIMULATION (SCS) DEVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NEUROPATHIC PAIN MARKET IN 2021 & 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE NEUROPATHIC PAIN MARKET

FIGURE 16 ESTIMATED CASES OF PERIPHERAL NEUROPATHY IN AMERICAN POPULATION

FIGURE 17 PREVALENCE OF NEUROPATHIC PAIN IN TYPE 1 AND TYPE 2 DIABETES

FIGURE 18 europe Neuropathic pain market: BY type, 2020

FIGURE 19 europe Neuropathic pain market: BY type, 2020-2028 (USD Million)

FIGURE 20 europe Neuropathic pain market: BY type, CAGR (2020-2028)

FIGURE 21 europe Neuropathic pain market: BY type, LIFELINE CURVE

FIGURE 22 europe Neuropathic pain market: BY product type, 2020

FIGURE 23 europe Neuropathic pain market: BY product type, 2020-2028 (USD Million)

FIGURE 24 europe Neuropathic pain market: BY product type, CAGR (2020-2028)

FIGURE 25 europe Neuropathic pain market: BY product type, LIFELINE CURVE

FIGURE 26 europe Neuropathic pain market: BY procedure, 2020

FIGURE 27 europe Neuropathic pain market: BY procedure, 2020-2028 (USD Million)

FIGURE 28 europe Neuropathic pain market: BY procedure, CAGR (2020-2028)

FIGURE 29 europe Neuropathic pain market: BY procedure, LIFELINE CURVE

FIGURE 30 europe Neuropathic pain market: BY technology, 2020

FIGURE 31 europe Neuropathic pain market: BY technology, 2020-2028 (USD Million)

FIGURE 32 europe Neuropathic pain market: BY technology, CAGR (2020-2028)

FIGURE 33 europe Neuropathic pain market: BY technology, LIFELINE CURVE

FIGURE 34 europe Neuropathic pain market: BY modality, 2020

FIGURE 35 europe Neuropathic pain market: BY modality, 2020-2028 (USD Million)

FIGURE 36 europe Neuropathic pain market: BY modality, CAGR (2020-2028)

FIGURE 37 europe Neuropathic pain market: BY modality, LIFELINE CURVE

FIGURE 38 europe Neuropathic pain market: BY mode of purchase, 2020

FIGURE 39 europe Neuropathic pain market: BY mode of purchase, 2020-2028 (USD Million)

FIGURE 40 europe Neuropathic pain market: BY mode of purchase, CAGR (2020-2028)

FIGURE 41 europe Neuropathic pain market: BY mode of purchase, LIFELINE CURVE

FIGURE 42 europe Neuropathic pain market: BY pain type, 2020

FIGURE 43 europe Neuropathic pain market: BY pain type, 2020-2028 (USD Million)

FIGURE 44 europe Neuropathic pain market: BY pain type, CAGR (2020-2028)

FIGURE 45 europe Neuropathic pain market: BY pain type, LIFELINE CURVE

FIGURE 46 europe Neuropathic pain market: BY indication, 2020

FIGURE 47 europe Neuropathic pain market: BY indication, 2020-2028 (USD Million)

FIGURE 48 europe Neuropathic pain market: BY indication, CAGR (2020-2028)

FIGURE 49 europe Neuropathic pain market: BY indication, LIFELINE CURVE

FIGURE 50 europe Neuropathic pain market: BY end user, 2020

FIGURE 51 europe Neuropathic pain market: BY end user, 2020-2028 (USD Million)

FIGURE 52 europe Neuropathic pain market: BY end user, CAGR (2020-2028)

FIGURE 53 europe Neuropathic pain market: BY end user, LIFELINE CURVE

FIGURE 54 europe Neuropathic pain market: BY distribution channel, 2020

FIGURE 55 europe Neuropathic pain market: BY distribution channel, 2020-2028 (USD Million)

FIGURE 56 europe Neuropathic pain market: BY distribution channel, CAGR (2020-2028)

FIGURE 57 europe Neuropathic pain market: BY distribution channel, LIFELINE CURVE

FIGURE 58 EUROPE neuropathic Pain market: SNAPSHOT (2020)

FIGURE 59 EUROPE neuropathic Pain market: BY COUNTRY (2020)

FIGURE 60 EUROPE neuropathic Pain market: BY COUNTRY (2021 & 2028)

FIGURE 61 EUROPE neuropathic Pain market: BY COUNTRY (2020 & 2028)

FIGURE 62 EUROPE neuropathic Pain market: BY Product & services (2021-2028)

FIGURE 63 Europe Neuropathic Pain MARKET: SNAPSHOT (2020)

FIGURE 64 Europe Neuropathic Pain MARKET: BY COUNTRY (2020)

FIGURE 65 Europe Neuropathic Pain MARKET: BY COUNTRY (2021 & 2028)

FIGURE 66 Europe Neuropathic Pain MARKET: BY COUNTRY (2020 & 2028)

FIGURE 67 Europe Neuropathic Pain MARKET: BY product & Services (2021-2028)

FIGURE 68 Europe Neuropathic Pain market: company share 2020 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The Europe Neuropathic Pain Market will be worth USD 2,371.40 million by 2030.
The Europe Neuropathic Pain Market growth rate is 9.1% during the forecast period.
Increasing Prevalence of Neuropathic Pain & Advances in Medical Research are the growth drivers of the Europe Neuropathic Pain Market.
The type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end user and distribution channel are the factors on which the Europe Neuropathic Pain Market research is based.
Abbott announced that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes & Vertex Pharmaceuticals Incorporated announced positive Phase 2 results of VX-548 in Acute and Neuropathic Pain by U.S. Food and Drug Administration are the latest developments in the Europe Neuropathic Pain Market.